The public subscription window for the NSDL IPO is open today, July 30, and will conclude on August 1. Ahead of the IPO, the company has raised ₹1201 crore from its anchor investors on July 29, 2025.
NSDL IPO is a book-building issue of ₹4,011.60 crores, consisting entirely of an offer for sale of 5.01 crore shares. The price band is set between ₹760 and ₹800 per share. The basis of allotment will be finalised by August 4, 2025, and the tentative listing date on BSE is August 6, 2025.
[30-July-2025 5:00:00 PM]
Investor Category |
Subscription (Times) |
Qualified Institutional Buyers (QIBs) |
0.84 |
Non-Institutional Investors |
2.83 |
Retail Individual Investors (RIIs) |
1.86 |
Employees |
3.68 |
Total |
1.78 |
The company will not receive any proceeds from the OFS component and will directly go to the selling shareholders.
Check out newly Listed IPOs on BSE and NSE.
As of 30 July 2025, NSDL IPO’s GMP stood at ₹126. The estimated listing price is ₹926, i.e., a 15.75% gain per share over the upper price band.
Source: Livemint Report dated 24 June, 2025 Disclaimer: The GMP (Grey Market Premium) price is an unauthenticated market related news and has no discernible basis. The same quoted above is as per news appeared in the media report and is for information purposes only. The investor shall do their own study/research before using the same for taking any decision to invest. We neither engage in, trade, or deal in the grey market nor we recommend or endorse trading in the grey market. |
Explore other Upcoming IPOs on BSE and NSE.
National Securities Depository Limited (NSDL), established in 1996, is India’s first and largest depository that facilitates the holding and transfer of securities in electronic form. NSDL operates under the regulatory supervision of the Securities and Exchange Board of India (SEBI) and provides a robust depository framework that allows investors to participate in the financial and securities markets in India.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory. To read the RA disclaimer, please click here |